Highlights d Cryo-EM structures of apo and substrate-bound MRP1 at 3.5 and 3.3 Å , respectively 
INTRODUCTION
Chemotherapy drug resistance in cancer patients is a major obstacle to effective treatment. Drug resistance is mediated by ATP-binding cassette (ABC) transporters, including P-glycoprotein (P-gp), the breast cancer resistance protein ABCG2, and several isoforms of the multidrug resistance protein (MRP) (Leslie et al., 2005) . These transporters harness the energy of ATP to actively pump drugs out of cancer cells before they can reach their intracellular targets and take effect. The same transporters also are major impediments to successful treatment of neurological disorders, as they are present at the blood-brain-barrier (BBB) and extrude xenobiotics from the CNS (Dallas et al., 2006) . MRP1, also known as ABCC1, was first identified in 1992 from drug-resistant lung cancer cells that did not express P-gp (Cole et al., 1992) . MRP1 was later shown to play a role in drug resistance in acute myeloblastic and lymphoblastic leukemia, non-small-cell lung cancer, prostate cancer, breast cancer, and neuroblastoma (Cole, 2014 ). MRP1 transports a wide variety of anticancer drugs, including but not limited to vincristine, etoposide, anthracyclines, and methotrexate. MRP1 has also been shown to transport other drugs used in the treatment of nonmalignant diseases, including some opiates, antidepressants, statins, and antibiotics. In addition to its role in the cellular extrusion of xenobiotics, MRP1 exports several other physiologically important molecules. These include pro-inflammatory molecules (e.g., leukotriene C 4 ), hormones (e.g., estrogens and prostaglandins), and antioxidants (e.g., oxidized and reduced glutathione). The substrates of MRP1 are structurally diverse and are typically amphipathic organic acids with large hydrophobic groups.
Although both are ABC transporters, MRP1 and P-gp differ substantially in their biochemical and pharmacological properties as well as their physiological functions. The two transporters share only 23% sequence identity; whereas P-gp contains the canonical domain architecture of ABC transporters with two functional ATP hydrolysis sites, MRP1 has an additional N-terminal transmembrane domain (TMD0) and contains only a single functional ATP hydrolysis site (Leslie et al., 2005) . The functional role of P-gp is mostly limited to the extrusion of xenobiotics. MRP1 exports both endobiotics and xenobiotics and thus influences physiological processes other than drug distribution (Cascorbi, 2011; Cole, 2014) . The chemical nature of their substrates also differs: P-gp recognizes hydrophobic substrates, whereas MRP1 mostly transports organic anions, many of which require conjugation with glutathione (GSH, g-Glu-Cys-Gly), glucuronic acid, or sulfate.
While the molecular structure of P-glycoprotein has been widely reported, until now MRP1 has remained refractory to structural analysis (Aller et al., 2009; Jin et al., 2012; Li et al., 2014; Szewczyk et al., 2015; Ward et al., 2013) . Here, we present electron cryomicroscopy (cryo-EM) structures of MRP1 in two conformations. These structures show for the first time how a eukaryotic ABC transporter recognizes its substrate and how substrate binding stimulates ATP hydrolysis.
and hydrolyze ATP as well as an additional N-terminal TMD known as TMD0. Our structural studies focus on bovine MRP1 (bMRP1). The sequence of bMRP1 is 91% identical to that of the human transporter (hMRP1). Expression of bMRP1 in human carcinoma cells confers resistance to the anti-cancer drugs vincristine, actinomycin D, and vinblastine as efficiently as cells expressing hMRP1, underscoring the functional similarity between the human and bovine transporters (Taguchi et al., 2002) .
Here, we further demonstrate that detergent-purified bMRP1 is an active ATPase with properties similar to hMRP1 (Figure 1 ). Both the K M for ATP (400 mM) and the maximal basal turnover rate (4.7 min À1 ) of bMRP1 ( Figure 1A ) are similar to those reported for the human transporter (70-400 mM and 2 min À1 , respectively) (Bakos et al., 2000b; Loe et al., 1996; Mao et al., 1999 Mao et al., , 2000 . The apparent affinities of bMRP1 for its substrates, reduced GSH and leukotriene C 4 (LTC 4 ), are also similar to those of the human transporter. Plotting the ATPase activity as a function of substrate concentration shows that GSH and LTC 4 both stimulate the ATPase activity by about 2.8-fold at saturating concentrations ( Figures 1B and 1C ). Our measured K M values for reduced GSH and LTC 4 are 0.9 mM and 350 nM, respectively; these values are close to those reported for hMRP1 in membrane vesicles (K M for GSH 1-5 mM and K M for LTC 4 100-370 nM) Leslie et al., 2003; Loe et al., 1996; Mao et al., 2000; Paulusma et al., 1999; Renes et al., 1999; Salerno and Garnier-Suillerot, 2001 ).
To test if TMD0 influences the activity of bMRP1, we generated a truncation mutant devoid of the N-terminal 203 residues (DTMD0). The functional properties of the DTMD0 construct, including the K M value for ATP (240 mM), maximal basal turnover rate (4.2 min À1 ), and the level of stimulation by substrates (1.8-to 2.4-fold) are comparable to those of the full-length protein (Figures 1D and 1E) . These results are consistent with studies of hMRP1 showing that the TMD0 deletion mutant possesses no functional defects in transport and nucleotide-trapping assays (Bakos et al., 1998) .
Structural Overview
Cryo-EM reconstructions were generated from datasets collected on full-length bMRP1 in the absence of any ligand (apo) and in complex with LTC 4 (Figures 2A and 2B ). The overall resolution for the apo structure is 3.5 Å , and the resolution for the LTC 4 -bound form is 3.3 Å ( Figure S1 ). The local resolution, estimated by blocres from the Bsoft package, varies from around 2 Å in TMD1 and TMD2 to about 5 Å in TMD0 ( Figure S2 ) (Heymann and Belnap, 2007) . In both reconstructions, regions corresponding to TMD1 and TMD2 have well-defined density, allowing us to unambiguously build and register all transmembrane helices in these regions de novo ( Figures 2C and S3 ). The densities corresponding to the NBDs were sufficient for us to dock the crystal structures of isolated NBDs into the map and manually adjust side chain positions based on the EM density ( Figure S3 ). In the region corresponding to TMD0, densities for five transmembrane helices were clearly visible but not sufficient to establish connectivity between the helices or to assign the amino acid register (Figure S4 ). The final structures, which contain nearly complete atomic models for TMD1, TMD2, NBD1, and NBD2, as well as a polyalanine model of TMD0, were refined against the EM maps to good statistics and excellent stereochemistry ( Figure S1 ; Tables S1 and S2).
The molecular structure of MRP1 (Figure 3 ) agrees well with the topology predicted from its sequence and biochemical data Slot et al., 2011) . The N-terminal TMD0 contains five transmembrane helices followed by an interfacial domain known as the lasso motif ( Figures 3A and 3B ) (Zhang and Chen, 2016) . The rest of the molecule forms a transporter core similar to other inward-facing ABC exporters such as P-gp, ABCB10, and the transporter associated with antigen processing (TAP) (Aller et al., 2009; Oldham et al., 2016b; Shintre et al., 2013) . The 12 transmembrane helices from TMD1 and TMD2 are arranged into two pseudosymmetric bundles: bundle 1, comprising TM helices 6, 7, 8, 11, 15, and 16; and bundle 2, comprising TM helices 9, 10, 12, 13, 14 , and 17 ( Figure 3C) . A large transmembrane vestibule, (A) ATPase activity of the full-length protein purified in digitonin. By nonlinear regression of the Michaelis-Menten equation, the K M for ATP was determined to be 400 ± 60 mM and the maximal ATPase activity was determined to be 27 ± 1 nmol/mg/min (assuming a pre-glycosylation molecular weight of 172 kDa, the specific ATP turnover rate is 4.7 min À1 ).
(B and C) ATPase activity of the full-length MRP1 as a function of GSH (A) and LTC 4 (B) concentrations. The protein and ATP concentrations were kept at 800 nM and 4 mM, respectively, for all measurements. The dashed lines represent the ATPase activity at 4 mM ATP in the absence of substrate. The K M value determined for GSH was 0.9 ± 0.2 mM and for LTC 4 was 350 ± 90 nM.
(D) ATPase activity of the truncation mutant devoid of TMD0. The K M for ATP was determined to be 240 ± 30 mM and the maximal ATPase activity was 28 ± 1 nmol/mg/min (or 4.2 min À1 , assuming a molecular weight of 148 kDa).
(E) At saturating concentrations (6 mM GSH or 20 mM LTC 4 ), substrates stimulate the ATPase activity of the full-length MRP1 and the truncation mutant to similar levels. All measurements were carried out at 28 C. The reported errors represent SD.
located at the interface of the two helical bundles, opens to the cytoplasm and penetrates halfway into the lipid bilayer. The two NBDs, located about 30 Å down into the cytoplasm, are completely separated from each other ( Figure 3B ). In the following sections, we will first describe several important structural features of MRP1. We will then discuss the specific interactions between LTC 4 and the transporter, the conformational changes that accompany substrate binding, and their mechanistic implications.
The N-Terminal Transmembrane Domain TMD0
The N-terminal TMD0 is a unique feature that is found only in five of the multidrug resistance proteins (MRP1, MRP2, MRP3, MRP6, and MRP7), the sulfonylurea receptors SUR1 and SUR2, and TAP. In SUR1, SUR2, and TAP, TMD0 is known to mediate interactions between the ABC transporter and other protein partners (Chan et al., 2003; Koch et al., 2004) . In SUR1 and SUR2, TMD0 associates with the inward-rectifying potassium channel K ir 6 to form a large ion channel known as the K ATP channel. In the case of TAP, TMD0 binds to tapasin to form the larger peptide-loading complex. The role of TMD0 in the multidrug resistance proteins, however, remains unclear, as no protein partners have been reported for these drug transporters.
Cryo-EM studies of the full-length TAP transporter revealed no density for the TMD0 domains, indicating their mobile nature in the absence of tapasin (Oldham et al., 2016a (Oldham et al., , 2016b . In the reconstructions of MRP1, we observed densities for all five transmembrane helices in TMD0 ( Figure S4 ). These helices pack closely together to form a compact structure that is tethered to one side of the molecule ( Figure 3B ). Contacts between TMD0 and the rest of the transporter are very limited. No interactions are present in the transmembrane region. There may be some inter-domain interactions mediated by cytoplasmic and extracellular loops; however, densities for these loops were insufficient to model specific interactions ( Figure S4 ).
The Interfacial Lasso Motif
Unlike TMD0, whose functional role has yet to be defined, the L 0 linker following TMD0 is essential for MRP1 folding and function (Bakos et al., 1998 (Bakos et al., , 2000a Westlake et al., 2003) . Removal of TMD0 along with the L 0 linker, or L 0 alone, resulted in defective transporters. Remarkably, co-expression of the L 0 peptide with the C-terminal transporter core restored proper trafficking and function of the core, leading to the conclusion that the L 0 peptide forms a structural motif that interacts with the transmembrane region of the core (Bakos et al., 1998) . Consistent with these functional data, residues 205-268 in the L 0 linker fold into an unusual structure packed tightly against TM7, TM15, and TM16 at the membrane/cytosol interface ( Figure 4A ). An amphipathic helix inserts diagonally into the inner leaflet of the membrane. Studies have shown that removing this helix from the L 0 peptide eliminates its ability to rescue the DL 0 mutants (Bakos et al., 2000a) .
The sequence of L 0 is conserved in all 13 members of the ABCC subfamily, even those that do not possess TMD0 such as the cystic fibrosis transmembrane conductance regulator (CFTR). We previously observed the structure of this region in CFTR and referred to it as the lasso motif (Zhang and Chen, 2016) . CFTR is an ATP-gated anion channel, whereas MRP1 is an ATP-driven multidrug pump. Despite the completely different functions of CFTR and MRP1, the structures of the CFTR lasso motif and the MRP1 L 0 linker are very similar (Ca root-meansquare deviation [RMSD] of 1.1 Å ) ( Figure 4B ). The CFTR lasso motif has been shown to interact with the membrane trafficking machinery, and similar to the MRP1 DL 0 constructs, mutations in the lasso motif cause defects in trafficking and gating, some of which lead to cystic fibrosis (Bilan et al., 2004; Fu et al., 2001; Gené et al., 2008; Jurkuvenaite et al., 2006; Naren et al., 1998 Naren et al., , 1999 Peters et al., 2001; Prince et al., 1999) . Thus, it seems that a common function of the lasso motif is to facilitate proper folding and trafficking of ABCC proteins. Future studies will clarify whether it also plays a specific role in CFTR gating or recruiting substrates to MRP1, as suggested in some studies (Fu et al., 2001; Naren et al., 1999; Westlake et al., 2003) .
The Nucleotide-Binding Domains During the transport cycle, the two NBDs dimerize to form two composite ATPase sites, each consisting of Walker A/B motifs from one NBD and the signature motif from the other. ATP hydrolysis is catalyzed via a general base mechanism, in which a glutamate residue polarizes the hydrolytic water for inline attack of the ATP g-phosphate (Geourjon et al., 2001; Moody et al., 2002; Oldham and Chen, 2011b) . In NBD1 of MRP1, however, the corresponding residue is an aspartate whose side chain may be too short to interact with the hydrolytic water. The other component of the same ATPase site, the NBD2 signature motif, also deviates from the consensus LSGGQ sequence. Thus, based on these deviations from the consensus sequences, MRP1 appears to have only one competent ATPase site. Indeed, it has been demonstrated experimentally that while both ATPase sites bind ATP, hydrolysis occurs primarily at the NBD2 site (Gao et al., 2000; Hou et al., 2000; Nagata et al., 2000; Payen et al., 2005) . In the structure of the apo form, the ATPase sites of the two NBDs are unevenly separated. The distance between the Walker A motif and the signature motif is 31 Å in the consensus site and 39 Å in the degenerate site ( Figure 6C) . A significant structural difference between the two NBDs occurs at their interfaces with the TMDs (Figures 4C and 4D ). The NBD2/TMD interface resembles the ''ball-and-socket'' joint observed in other ABC transporters, where a cytoplasmic helix from the TMD (the ball) docks into a cleft on the NBD surface (the socket). In NBD1, however, an important structural element of the socket (b-strand s2 and a-helix h5) is missing due to a deletion of 13 residues ( Figures 4C and 4D) . The deletion of 10-13 residues in NBD1 is a conserved feature that has been long noted for ABCC proteins . It is now clear that this deletion renders the NBD1/ TMD interface much weaker, and in CFTR, this region is prone to a high frequency of disease-causing mutations (Zhang and Chen, 2016) .
Another interesting feature common to CFTR and MRP1 is a key aromatic residue at the NBD1/TMD interface. In MRP1, F728 in NBD1 forms extensive van der Waals interactions with hydrophobic residues on TMD2 ( Figures 4C and S3) . It also makes a cation-p interaction with R1172 from TM16 ( Figure S3 ). In CFTR, the equivalent residue is F508, whose deletion accounts for 70% of cystic fibrosis cases, highlighting the essential role of this single residue in maintaining the structural integrity of an ABCC transporter (Cheng et al., 1990) .
Substrate Recognition
The cryo-EM reconstruction of the LTC 4 -bound form yielded a map at an even higher resolution than the apo form versus 3.5 Å ). The densities in the transmembrane region are particularly well resolved ( Figures S2 and S3 ), thus enabling us to define the position of LTC 4 and the chemistry of substrate recognition ( Figures 5A and 5B) .
The pro-inflammatory mediator LTC 4 is one of the physiological substrates of MRP1. LTC 4 is a cysteinyl leukotriene that is produced and excreted by immune cells as part of the inflammatory response and contributes to anaphylaxis in pathologies such as asthma . It contains an arachidonic acid derivative covalently conjugated to the tripeptide GSH. LTC 4 binds to MRP1 inside the transmembrane pathway between the two TM bundles about 10 Å into the membrane from the cytoplasm ( Figure 5A ). It forms a network of hydrogen bonds and van der Waals interactions with both TM bundles, fastening the two halves of the transporter together ( Figures 5C and 5D ). The extensive interactions between MRP1 and LTC 4 are consistent with the sub-micromolar affinity observed for LTC 4 (Loe et al., 1996) .
The binding site can be divided into two parts: a positively charged region that coordinates the GSH moiety (the P-pocket) and a largely hydrophobic area that encompasses the lipid tail (the H-pocket) ( Figures 5C and 5D ). Residues from both halves of the transporter form the P-pocket, in which the GSH moiety forms hydrogen bonds with K332, H335, Y440, R1196, N1244, and R1248. The GSH moiety also makes van der Waals contacts with nonpolar residues including L381, F385, and F594. The H-pocket is formed by residues from TM bundle 2 only, where the lipid tail of LTC 4 curls up to form a nearly flat surface stacked between a ''tryptophan sandwich'' formed by W553, M1092, and W1245. The outer edge of the tryptophan sandwich is lined by Y1242 and the g-methyl group of T550. Most of the molecular surface in LTC 4 is buried between the two TM bundles, with the exception of the carboxylate of the arachidonic acid moiety, which points toward the cytoplasm between F594 and M601 and is exposed to solvent inside the translocation pathway.
Remarkably, the bipartite nature of the substrate-binding site was predicted by Loe et al. (1996) about 20 years ago based on the ability of MRP1 to recognize large, amphipathic substrates. Consistent with our EM structure ( Figures 5C and 5D ), K332 was pinpointed to interact with the g-glutamate of GSH and GSH-containing molecules (Maeno et al., 2009) . Furthermore, even the modest replacement of Y440 with a phenylalanine reduced LTC 4 and GSH-stimulated substrate transport, underscoring the importance of the hydrogen bond observed between the GSH moiety and the hydroxyl of Y440 in molecular recognition (Grant et al., 2008) . Functional studies suggest that the very residues shown to interact with LTC 4 in our structure are also involved in binding other substrates of MRP1. For example, mutating individual residues corresponding to K332, H335, W553, F594, R1196, W1245, and R1248 in hMRP1 results in severely diminished or complete loss of transport of many substrates (Campbell et al., 2004; Haimeur et al., 2002 Haimeur et al., , 2004 Ito et al., 2001; Koike et al., 2002; Ren et al., 2002; Situ et al., 2004) .
Substrate Binding Primes MRP1 for ATP Hydrolysis
Structural comparison of MRP1 in the apo and LTC 4 -bound states reveals both local and global conformational changes induced by substrate binding (Figure 6 ). Even at the 2D classification stage, it is apparent that the NBDs are closer together in the presence of LTC 4 (Figures 2A and 2B ). As LTC 4 binds at the interface of the two TM bundles, it serves as a connecting bridge to bring the two halves of the transporter closer together. This is achieved by rotations of two rigid bodies, one consisting of the lasso motif, TM bundle 1, and NBD1, and the other consisting of TM bundle 2 and NBD2 (Figures 6A and S5 ; Movie S1). Superposition of each of the two rigid bodies from the apo and LTC 4 -bound forms yields Ca RMSD values of <1 Å ( Figure S5 ).
At the binding site, the two TM bundles move 2-4 Å toward each other to interact with LTC 4 . Several residues, including W553, N1244, W1245, and R1248, reposition their side chains to form proper interactions with LTC 4 ( Figure 6B ; Movie S2). These small displacements at the LTC 4 -binding site are propagated over 50 Å to the cytoplasmic NBDs. Consequently, the NBDs move about 12 Å closer upon LTC 4 binding and their orientations relative to one another are also changed. In the apo structure, the two NBDs are twisted relative to each other, as indicated by the uneven separations between the two ATPase sites ( Figure 6C ). In the LTC 4 -bound structure, both sites are about 22 Å apart, with the Walker A and signature motifs from opposite NBDs better in line with each other ( Figure 6C ).
The conformational differences between the apo and LTC 4 -bound structures provide a molecular explanation of the elevated ATPase activity in the presence of LTC 4 ( Figure 6D ). ATP hydrolysis occurs when the two NBDs dimerize to form a complete catalytic site. LTC 4 stabilizes a conformation in which the NBDs are closer and better aligned. Thus, the probability of NBD dimerization through thermal fluctuations is higher in the presence of LTC 4 . Previous studies of the maltose transporter have shown that association of the substrate-loaded binding protein brings the two NBDs into contact to form a semi-open dimer. This conformational change is accompanied by a >300-fold stimulation of ATPase activity (Davidson et al., 1992; Oldham and Chen, 2011a) . By comparison, the substrate-induced conformational changes observed in MRP1 are much smaller, consistent with the modest stimulation (2-to 3-fold) of ATP hydrolysis (Figure 1 ).
DISCUSSION
A fundamental puzzle regarding multidrug resistance is how a single transporter recognizes many structurally dissimilar molecules. Our structures of MRP1 show that by forming a single bipartite substrate-binding site, MRP1 can recognize a spectrum of substrates with different chemical structures. The H-pocket is larger than the lipid tail of LTC 4 and is thus able to accommodate other hydrophobic moieties. There are also a few polar side chains in the H-pocket, including Q1088 (a glutamate in hMRP1) and S1096 ( Figure 5C ), that could interact with polar functional groups located on otherwise hydrophobic substrates.
In addition, many residues in the binding site undergo local rearrangements in their side-chain positions upon binding to LTC 4 , highlighting the plasticity within the binding site that allows for adaptability to a variety of substrates.
The observation that GSH is itself a substrate of MRP1 can easily be explained by the fact that the P-pocket comprises both TM bundles, and therefore GSH can bridge the two halves of the transporter on its own Leslie et al., 2003; Paulusma et al., 1999; Renes et al., 1999; Salerno and Garnier-Suillerot, 2001 ). Understandably, GSH is a much lower affinity substrate than LTC 4 (millimolar versus nanomolar) owing to additional favorable interactions formed between the lipid moiety of LTC 4 and the H-pocket. Some substrates can be transported without a GSH moiety, such as methotrexate or substrates conjugated to sulfate or glucuronic acid. These substrates are amphipathic, possessing both negatively charged and hydrophobic functional groups and are therefore likely to interact with both the P-and H-pockets for high-affinity binding.
P-gp and MRP1 are both ABC transporters that confer multidrug resistance. These two transporters show substantial differences in their functional properties, some of which can now be explained on the basis of their molecular structures. The chemical environments of the translocation pathways in P-gp and MRP1 are very different, as each pathway complements the chemical properties of its substrates. P-gp transports hydrophobic compounds and some weakly cationic substrates whereas MRP1 transports mostly organic acids (Seelig, 1998) . When viewed as an electrostatic surface, the translocation pathway of P-gp is hydrophobic with some acidic patches, while that of MRP1 is basic ( Figures 7A and 7B) . Furthermore, MRP1 and P-gp likely utilize different mechanisms of substrate recruitment. P-gp functions via the ''hydrophobic vacuum'' model, in which substrates first partition into the inner leaflet of the lipid bilayer and then enter the transporter directly from the membrane rather than from the cytoplasm (Higgins and Gottesman, 1992) . Accordingly, the translocation pathway of P-gp is open to the cytoplasm as well as the inner leaflet of the membrane ( Figure 7C ). The helices lining this membrane opening are flexible and have been proposed to serve as an intramembranous gate, allowing for substrates of different sizes to access the transporter directly from the inner leaflet (Jin et al., 2012; Kodan et al., 2014) . In support of this model, P-gp is 100-4,000 times more sensitive to drugs in the lipid bilayer than in detergent micelles (Jin et al., 2012) . Such a mechanism, whereby transport depends on an elevated local concentration of drug through membrane partitioning, also implies that the intrinsic affinity of drugs for the transporter itself may be low, consistent with the ability of P-gp to transport many structurally different compounds. In contrast, the translocation pathway of MRP1 is completely shielded from the membrane and only accessible from the cytoplasm ( Figure 7D ). The See also Figure S5 and Movies S1 and S2.
transmembrane helices of MRP1 are well ordered with no helical breaks. The apparent affinities of MRP1 for its substrates are very similar in detergent micelles and in the lipid bilayer ( Figure 1 ). Therefore, unlike P-gp, MRP1 likely recruits its substrates directly from the cytoplasm. The ability of MRP1 to recognize different substrates does not depend on membrane partitioning of the substrate. Instead, it originates from the bipartite nature and plasticity of its single substrate-binding site.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Culture Sf9 cells were cultured in sf-900 II SFM medium (GIBCO) supplemented with 5% FBS at 27 C. HEK293S GnTI -suspension cells were cultured in Freestyle 293 medium (GIBCO) supplemented with 2% FBS at 37 C with 8% CO 2 and 80% humidity.
METHOD DETAILS Expression and purification of bovine MRP1
The gene encoding bovine MRP1 was codon-optimized for expression in mammalian cells and synthesized by Bio Basic Inc. The gene was cloned into a donor plasmid containing a C-terminal PreScission-Protease-cleavable GFP tag and transformed into DH10Bac cells to generate recombinant bacmid. Purified bacmid was transfected into Sf9 insect cells using Cellfectin II reagent (Thermo Fisher) and the resulting baculovirus was amplified to P4 in Sf9 cells maintained in Sf-900 II SFM media (GIBCO) supplemented with 5% FBS. The P4 baculovirus was added at 10% v/v to HEK293S GnTI -suspension cells at a density of 2.5-3.5 million cells/mL in FreeStyle 293 media (GIBCO) supplemented with 2% FBS and grown with shaking at 37 C with 8% CO 2 and 80% humidity. After 18-20 hr, 10 mM sodium butyrate was added and the temperature was dropped to 30 C (Goehring et al., 2014) . Cells were harvested 48 hr later, flash-frozen in liquid nitrogen, and stored at À80 C. 
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